Brower Piven, A Professional Corporation, has commenced an investigation of potential securities law violations by Dynavax Technologies Corporation (“Dynavax” or the “Company”) (NasdaqCM: DVAX).
The investigation of Dynavax is related to positive statements issued by Dynavax concerning its investigational hepatitis B vaccine, Heplisav. On June 10, 2013, the Company disclosed that the U.S. Food and Drug Administration required additional data regarding the safety of Heplisav before it could further review the drug for potential approval. The price of Dynavax shares declined significantly following this news.
If you purchased Dynavax common stock between July 20, 2011 and June 10, 2013, the period during which Dynavax common stock may have been overvalued due to possibly misleading statements by the Company, and would like to learn more about the investigation being conducted by Brower Piven, you may email or call Brower Piven, who will, without obligation or cost to you, attempt to answer your questions. You may contact Brower Piven by email at
firstname.lastname@example.org, by calling 410/415-6616, or at Brower Piven, A Professional Corporation, 1925 Old Valley Road, Stevenson, Maryland 21153. Attorneys at Brower Piven have combined experience litigating securities and class action cases of over 60 years.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts